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The metabolic enzyme phosphoglycerate mutase 1
(PGAM1) is overexpressed in several types of cancer,
suggesting an additional function beyond its estab-
lished role in the glycolytic pathway. We here report
that PGAM1 is overexpressed in gliomas where it in-
creases the efficiency of the DNA damage response
(DDR) pathway by cytoplasmic binding of WIP1
phosphatase, thereby preventing WIP1 nuclear
translocation and subsequent dephosphorylation of
the ATM signaling pathway. Silencing of PGAM1
expression in glioma cells consequently decreases
formation of g-H2AX foci, increases apoptosis, and
decreases clonogenicity following irradiation (IR)
and temozolomide (TMZ) treatment. Furthermore,
mice intracranially implanted with PGAM1-knock-
down cells have significantly improved survival after
treatment with IR and TMZ. These effects are coun-
teracted by exogenous expression of two kinase-
dead PGAM1 mutants, H186R and Y92F, indicating
an important non-enzymatic function of PGAM1.
Our findings identify PGAM1 as a potential therapeu-
tic target in gliomas.
INTRODUCTION
Transformation of normal cells into rapidly proliferating cancer
cells requires alterations of cell cycle checkpoints that act to
regulate cellular proliferation (Hartwell and Kastan, 1994). DNA
damage repair (DDR) is one of the major pathways that prevent
normal cells from transforming into cancer cells. In normal cells,
the DDR pathway is activated upon exposure to agents that
induce DNA damage that require repair. The DDR pathway is de-
activated once the DNA repair process is complete (Kim and
Haber, 2009); if the DNA lesion cannot be repaired, the cell
undergoes cellular senescence or apoptosis. In cancer cells,
however, the pathway is constitutively active. Current cancer
treatments, such as irradiation (IR) and chemotherapy, attempt
to induce DNA lesions to levels that surpass the ability of theThis is an open access article under the CC BY-Ncell to repair all of the DNA damage, ultimately leading to cell
death (Curtin, 2013). Cancer cells, however, are often efficient
in repairing the DNA damage and thus can avoid senescence
and cell death.
Recent findings suggest that cellular metabolism is altered in
cancer cells in order to support the needs of indefinite prolifera-
tion by performing functions that are not fully understood
(DeBerardinis and Chandel, 2016; Pavlova and Thompson,
2016). Several enzymes in the glycolytic pathway, such as hex-
ose kinase II (HKII), pyruvate kinase-M2 (PKM2), phospho-fructo
kinase (PFK), enolase, and phosphoglycerate mutase (PGAM1),
are aberrantly overexpressed in cancer cells (Wolf et al., 2011;
Mukherjee et al., 2013, 2016; Capello et al., 2011; Vander Heiden
et al., 2010). PGAM1 converts 3-phosphoglycerate (3-PG) into 2-
phosphoglycerate (2-PG) using phospho-histidine11 as a phos-
phate donor/acceptor site within its catalytic domain through
formation of a 2,3-bisphosphoglycerate intermediate (Vander
Heiden et al., 2010; Hitosugi et al., 2012). PGAM1 is expressed
at various levels within various normal tissues during cellular dif-
ferentiation or transformation (Jiang et al., 2014). Furthermore,
PGAM1 is overexpressed in several types of cancer, including
gliomas (Sanzey et al., 2015; Liu et al., 2018).
PGAM1 is unique among the glycolytic enzymes in that its
transcription is regulated by the tumor suppressor p53 (Cheung
and Vousden, 2010), and increased expression of PGAM1 has
been reported to immortalize primary cells through an unknown
mechanism (Kondoh et al., 2005). Cancer cells that express
PKM2 have increased levels of phosphorylated PGAM1 at resi-
due histidine11, which leads to increased mutase activity and
results in increased production of PEP. This positive feedback
loop of PEP production and enzymatic activity of PGAM1 may
act as an alternate route to funnel more metabolites into the
biosynthetic arm of the glycolysis pathway (Vander Heiden
et al., 2010). The benefit of PGAM1 overexpression was attrib-
uted toward increased glycolysis and biosynthesis via the
pentose phosphate pathway (PPP), thereby promoting cancer
cell proliferation and tumor growth that can be reversed using
genetic and pharmacological approaches to inhibit PGAM1 ac-
tivity (Hitosugi et al., 2012). Previously, a chemical genomics
screen identified the compound MJE3 as a non-specific target
of PGAM1 that inhibits PGAM1 enzyme activity and breast can-






Figure 1. PGAM1 Is Overexpressed in Gliomas
(A) Triplicate quantitative PCR analysis of the level of PGAM1 transcripts in human non-neoplastic normal brain (NB) and grade I (Gr-1), grade II (Gr-2), grade III
(Gr-3), and grade IV (Gr-4) astrocytomas; n = 5 for each group numbered 1–5.
(B) Triplicate quantitative PCR analysis of the level of PGAM1 transcripts in normal human astrocytes (NHAs) and three glioma cells lines, U87, LN319, and U251.
(C) TCGA-based analysis of PGAM1mRNA levels in grade II (Gr-2), grade III (Gr-3), and grade IV (Gr-4) astrocytomas relative to normal brain controls (1.0 on the y
axis).
(legend continued on next page)
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revealed that Y26 phosphorylation of PGAM1 leads to increased
activation by releasing E19 from the active site, which stabilizes
binding of cofactor 2,3-bisphosphoglycerate and H11 phos-
phorylation (Hitosugi et al., 2013).
Recent studies have demonstrated that PGAM1 enzyme activ-
ity also has a non-metabolic role in homologous recombination
(HR)-mediated DDR. PGAM1 enzyme activity regulates stability
of CTBP-interacting protein (CtIP), a HR component that medi-
ates replication protein A recruitment and Rad51 filament forma-
tion (Qu et al., 2017). On the other hand, enzymatically dead
PGAM1 demonstrated interesting non-metabolic function by
promoting cancer metastasis. PGAM1 interacts with a-smooth
muscle actin (ACTA2) and thereby modulates actin filaments as-
sembly, cell motility, and cancer cell migration independent of its
metabolic activity. Enzymatically inactive H186Rmutant PGAM1
can bind ACTA2, whereas metabolically active, 201–210 amino
acid-deleted PGAM1 cannot. In a xenograft model, decreased
metastasis was observed with PGAM1 loss and was found to
be prognostic in human breast cancer patients along with
ACTA2 (Zhang et al., 2017).
Here we report that PGAM1 is overexpressed in human gli-
omas across all grades (I–IV) and in established glioma cell lines.
This overexpression of PGAM1 indirectly increases the efficiency
of DDR and increases resistance to IR and temozolomide (TMZ)
treatment. In addition, we show that PGAM1 traps WIP1 in the
cytoplasm, thereby controlling phosphorylation of major cell cy-
cle checkpoint proteins, such as ATM, Chk1, Chk2, and g-H2AX.
Together, these data suggest that PGAM1 inhibitors that block
its interaction with WIP1 are ideal candidates to sensitize cells
against DNA-damaging therapeutic agents.
RESULTS
PGAM1 Is Overexpressed in Human Glioblastoma (GBM)
along with PGAM1 Activity
To determine if PGAM1 is expressed in primary brain tumors, we
examined RNA levels of PGAM1 in human gliomas (grades I–IV)
and normal brain obtained from frozen and formalin-fixed tissue
samples. Real-time PCR gene expression analysis was per-
formed with two independent sets of primers. As shown in Fig-
ure 1A, PGAM1 is overexpressed almost 4-fold in grade I tumors
compared with normal brain, suggesting that overexpression of
PGAM1 consistently occurs in gliomas from histologic grades I
to IV. World Health Organization (WHO) grade III and IV gliomas
express a small but statistically significant increase in PGAM1
expression compared with grade I tumors that is almost 5-fold
overexpressed compared with normal brain. To find an in vitro
model that resembles the PGAM1 overexpression found in hu-(D) PGAM1 activity (mean + standard error [SE]) determined using an assay cou
(Gr-2), grade III (Gr-3), and grade IV (Gr-4) astrocytomas; N = 5 for each group w
(E) Western blot verification of PGAM1 and b-actin protein levels in human norm
(Gr-4) astrocytomas.
(F) Western blot verification of PGAM1 and b-actin protein levels in normal human
and SF8279.
(G) Immunohistochemistry (IHC) analysis of representative fixed sections from tu
(H) Semiquantitative analysis (four-tiered scale) of IHC staining; N = 4 (NB), 5 (Gr-
were significantly larger than NB values (p < 0.05).
Except where noted, all values were derived from three independent experimentman tumors, we examined three established glioma cell lines
and compared themwith normal human astrocytes (NHAs) using
the same real-time PCR assay. Similar to primary human tumors,
established glioma cell lines showed an almost 3.5- to 4-fold in-
crease in PGAM1 expression compared with NHAs (Figure 1B).
Similarly, The Cancer Genome Atlas (TCGA) dataset analyses
demonstrated overexpression of PGAM1 compared with normal
brain in grade II–IV gliomas (Figure 1C). To determine if the
changes in PGAM1 expression noted at the RNA level were re-
flected in PGAM1 activity and protein expression, fixed material
and lysates from frozen samples used for RNA analysis were
subjected to a biochemical assay (to measure enzyme activity),
western blot, and immunohistochemical analysis. As demon-
strated by the biochemical assay, low-PGAM1-expressing
normal brain samples exhibited low levels of PGAM1 enzyme ac-
tivity, while the PGAM1 enzyme activity of the glioma samples
correlated well with increased expression of the PGAM1 tumor
mRNA (Figure 1D). As shown in the western blots in Figure 1E,
representative normal brain samples expressed significantly
less PGAM1 protein than brain tumor samples or commonly
used glioma cell lines and three primary glioma stem-like cells
(GSCs) established at the University of California, San Francisco
(UCSF) (Fouse et al., 2014;Mancini et al., 2018; Figure 1F). These
results were consistent with immunohistochemical analyses of
fixed tissue (Figure 1G), where semiquantitative analysis (Fig-
ure 1H) showed, as noted at the RNA level, that normal brain ex-
presses low levels of PGAM1 protein compared with tumor
samples.
Reductions in PGAM1 Expression Sensitize GBM Cell
Lines to IR and TMZ Treatment
Upregulation of PGAM1 may be an early event in tumorigen-
esis, suggesting that PGAM1 is critical for glioma growth. To
address this possibility, we modulated the expression of
PGAM1 and monitored the effect on in vitro and in vivo growth
of these cells. For these studies, U87, LN319, SF10602, and
SF7996 glioma cells were used, as these cells demonstrate
similar levels of PGAM1 mRNA and protein compared with hu-
man glioma samples (Figures 1B and 1F). Because all analyzed
astrocytomas upregulate PGAM1, and because suppression of
PGAM1 levels have been shown to inhibit tumor cell growth in
other systems (Hitosugi et al., 2012; Evans et al., 2005), we first
examined the consequences of PGAM1 knockdown in GBM
cells. As shown in the western blot in Figure 2A, the lentiviral
introduction of two different short hairpin RNAs (shRNAs) tar-
geting PGAM1 resulted in two independent populations of
GBM cells for each cell line, each of which exhibited significant
decreases in PGAM1 expression compared with parental andpled to the oxidation of NADH in normal brain (NB) and grade I (Gr-1), grade II
ere measured.
al brain (NB-1) and grade I (Gr-1), grade II (Gr-2), grade III (Gr-3), and grade IV
astrocytes (NHAs) and glioma cells lines U87, LN319, U251, SF10602, SF7996,
mors in (A) using PGAM1 antibody (bar, 100 mM).
1), 9 (Gr-2), 11 (Gr-3), and 10 (non-segregated Gr-4). All tumor PGAM1 values
s ± SD. *p < 0.05.
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empty vector controls. Decreased PGAM1 expression was
associated with a significant decrease in PGAM1 activity
(Figure 2B). In contrast to previously published data, PGAM1
suppression did not affect proliferation or colony formation
(Figures 2C and 2D) in any of the glioma cell lines. Interestingly,
when these PGAM1-knockdown cells were treated with IR and
TMZ, they showed significantly increased sensitivity compared
with the parental cells in terms of cell viability (Figures 2C and
2G) and apoptosis (Figures 2E and 2I; Figures S1A and S1B).
Moreover, these cells formed significantly fewer colonies (Fig-
ures 2D and 2H) than the parental cells. However, in contrast
to glioma cells, NHAs expressed low levels of PGAM1 and
were more susceptible to both IR and TMZ, which did not
further increase by PGAM1 silencing (Figures S1C and S1D),
and western blot analysis demonstrated the presence of
cleaved caspase-3 and cleaved PARP in PGAM1-knockdown
cells treated with IR and TMZ, consistent with induction of
apoptosis (Figures 2F and 2J). To mimic genetic loss, we
used pharmacological inhibitors (PGAM-tide and Alizarin) that
block PGAM1 enzyme activity (Hitosugi et al., 2012; Engel
et al., 2004; Figure S1E), but surprisingly this had no effect
on cell viability or apoptosis when combined with IR (Figures
S1F and S1G) and TMZ (Figures S1H and S1I) treatment.
Loss of PGAM1DecreasesDNADamageRepair Pathway
Activation Despite the Presence of DNADamage after IR
and TMZ Treatment
IR and TMZ treatment induce the formation of double-strand
DNA breaks and activation of the DDR pathway. We therefore
wanted to investigate if PGAM1 loss sensitizes GBM cells to IR
and TMZ treatment through regulation of the DDR pathway.
PGAM1-knockdown cells were subjected to IR and TMZ treat-
ment, and double-strand breaks were measured using a
single-cell comet assay performed under neutral pH conditions.
In the control cells, fragmented DNA resulting from the double-
strand breaks decreased over time, whereas fragmented DNA
remained elevated in PGAM1-knockdown cells. After ionizing ra-
diation treatment (10 Gy) in parental cells, the maximum number
of double-strand breaks was found after 24 h and began gradu-
ally decreasing by 72 h. In PGAM1-knockdown cells, the number
of double-strand DNA breaks remained unchanged from 24 h forFigure 2. Knocking Down PGAM1 Increases Sensitivity toward Ionizin
(A) Parental established U87, LN319, and stem-like SF10602 and SF7996 glioma c
shRNAs targeting PGAM1 (PGAM1 shRNA#1 and PGAM1 shRNA#2) andwere the
(B) PGAM1 activity (mean + SE) was determined in triplicate for each group usin
(C) Glioma cells from (A) were treated with and without ionizing radiation (IR; 10 Gy
the mean of three independent experiments performed in triplicate.
(D) Number of colonies (>50 cells) that arose 28 days following plating of the cel
(E) Apoptosis of glioma cells from (C) was measured using annexin V staining an
(F)Western blot analysis for cleaved caspase-3 and PARP in U87 and LN319 gliom
bands are marked with arrows.
(G) Glioma cell populations from (A) were treated with and without TMZ (100 mM) f
the mean of three independent experiments performed in triplicate.
(H) Number of colonies (>50 cells) that arose 28 days following plating of the cel
(I) Apoptosis of glioma cells from (G) were measured using annexin V staining an
(J)Western blot analysis for cleaved caspase-3 and PARP in U87 and LN319 gliom
bands are marked with arrows.
Except where noted, all values were derived from three independent experimentup to 7 days (Figure 3A). Similarly, after TMZ (100 mM) treatment
in parental cells, the maximum number of double-strand breaks
was detected after 72 h and then gradually declined, whereas it
remained elevated in PGAM1-knockdown cells for up to 7 days
(Figure 3B). Previously identified PGAM1 interactors such as
CtIP and ACTA2 had no significant effect on the extent of DNA
damage or the repair of DNA breaks, as demonstrated by small
interfering RNA (siRNA)-mediated knockdown followed by IR (10
Gy) treatment and comet assay (Figure S2A). But as expected,
treatment with IR (10 Gy) resulted in formation of g-H2AX foci
(a surrogate measure of double-strand DNA breaks) in parental
U87 and LN319 cells at day 1, which gradually decreased on
days 5 and 7, indicating efficient repair of DNA damage (Fig-
ure 3C). Very few g-H2AX foci were observed in U87 and
LN319 PGAM1-knockdown cells after IR treatment, which did
not change significantly over time (day 3 versus day 5 versus
day 7) (Figure 3C). Similarly, 3 h exposure of parental cells to
TMZ (100 mM) resulted in formation of g-H2AX foci beginning
2 days after drug treatment, with a gradual decrease at days 5
and 7. Contrary to the parental cells, few g-H2AX foci were
observed in PGAM1-knockdown cells after TMZ treatment,
which remained unchanged over time (Figure 3D). At early time
points, DNA breaks are infrequent until 12 h (Figure S2B).
Notably, NHAs treated with IR and TMZ showed significantly
higher level of DNA breaks compared to the parental glioma cells
and the DNA breaks in the NHAs were not similarly resolved with
time (Figure S2C). PGAM1 knockdown in NHAs did not provide
any significant additive changes in the extent of DNA breaks
and g-H2AX foci formation (Figures S2C and S2D).
Response to DNA damage is related to DDR efficiency, and
HR has previously been reported to be altered upon suppression
of PGAM1 (Qu et al., 2017). We therefore looked at HR and non-
homologous end joining (NHEJ) efficiency by using a plasmid-
based system using the ATM kinase inhibitor KU-55933 and
DNA ligase-4 inhibitor SCR-7 as a positive control for HR and
NHEJ inhibition. However, no change in HR or NHEJ efficiency
was observed in parental or PGAM1-knockdown cells (Fig-
ure S2E), whereas KU-55933 and SCR-7 significantly lowered
HR and NHEJ efficiency, respectively. This suggests that sup-
pression of PGAM1 does not regulate HR and NHEJ efficiency
in gliomas.g Radiation (IR) and TMZ in Glioma Cell Lines
ells were infected with lentivirus containing empty vector (EV) or one of the two
n established and analyzed using western blot for levels of PGAM1 and b-actin.
g an assay coupled to the oxidation of NADH.
), and cell viability was determined on day 5 using alamarBlue assay. Values are
ls from (C) in soft agar.
d flow cytometry assay after 3, 5, or 7 days of treatment.
a cells from (C). The cleaved 19 and 17 kDa caspase-3 protein bands and PARP
or 5 days, and cell viability was determined using alamarBlue assay. Values are
ls from (G) in soft agar.
d flow cytometry assay after 3, 5, or 7 days of treatment.
a cells from (G). The cleaved 19 and 17 kDa caspase-3 protein bands and PARP
s ± SD. *p < 0.05.




Figure 3. Loss of PGAM1 Decreases DDR Pathway Activation despite the Presence of DNA Damage after Radiation and TMZ Treatment
(A and B) Analysis of tail moment (a measure of DNA fragmentation) in cells from Figure 2A treated with IR (10 Gy) (A) and (B) treated with TMZ (100 mM) before
being harvested after 0, 1, 3, 5, and 7 days. Each data point represents the mean + SE of at least 100 cells per treatment.
(C and D) Representative photomicrographs of cells from Figure 2A treated with IR (10 Gy) (C) and (D) TMZ (100 mM) and subsequently analyzed for phospho-g-
H2AX foci (a measure of DNA double-strand break) by immunofluorescent staining with anti-Ser-139-phosphorylated H2AX antibody (in red) and counterstained
(legend continued on next page)
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Loss of PGAM1 Inhibits Phosphorylation of ATM and
Downstream Signaling
ATM is one of the major kinases involved in the cellular response
to DNA double-strand breaks, which may arise through the
collapse of stalled replication forks or through exposure to
DNA-damaging agents. Autophosphorylation of ser1981 is a reli-
able marker of ATM activation (Curtin, 2013). We therefore
treated U87 and LN319 cells with IR and TMZ, and performed
western blotting to determine whether ATM phosphorylation
would differ on the basis of PGAM1 expression. Phosphorylation
of ATM ser1981was readily observed in parental U87 and LN319
cells after both IR (10 Gy) and TMZ (100 mM) treatment as ex-
pected 48 h post-treatment (Figure 4A). At earlier time points
before 48 h, no change in phosphorylation of ATM ser1981
was observed (Figure S3A). In contrast, phosphorylation of
ATM ser1891 was not observed in PGAM1-knockdown U87
and LN319 cells after IR or TMZ treatment, indicating lack of
ATM activation in these cell populations (Figure 4A). Moreover,
in parental cells, IR treatment activated ATM and downstream
signaling, as observed by phosphorylation of Chk2 at thr68
and cdc25C at ser216. However, phosphorylation of Chk2
thr68 or cdc25 ser216 was not observed in PGAM1-knockdown
cells, which is consistent with deficient ATM signaling. TMZ
treatment in parental cells resulted in phosphorylation of
Chk1(ser345), Chk2(thr68), and cdc25C(ser216), which was not
observed in PGAM1-knockdown cells. Consequently, as
PGAM1-knockdown cells demonstrated loss of activating phos-
phorylation of Chk1 and Chk1, we found significantly increased
G2/M arrest followed by apoptosis in response to IR and TMZ
compared with corresponding parental cells (Figure 4B). To
determine if PGAM1 knockdown affects the protein kinase
ATR, an ATR kinase assay was performed on corresponding
PGAM1-proficient and PGAM1-deficient cells. Phosphorylation
of Chk1 in parental cells paralleled the activation of ATR, as
demonstrated by the presence of serine/threonine phosphoryla-
tion of the ATR substrate PHAS by ATR immunoprecipitates of
TMZ-treated cells. In contrast, in TMZ-treated PGAM1-knock-
down cells, ATR activation was observed, but there was no acti-
vation of Chk1, as demonstrated by lack of Chk1 ser345 phos-
phorylation (Figure 4C). Our observations collectively indicate
that PGAM1 expression is necessary for ATM downstream
signaling in response to IR and TMZ in glioma cells.
PGAM1 Influences WIP1 Cytoplasmic Localization
Because PGAM1 is mainly a cytoplasmic protein and may not be
directly regulatingdephosphorylationof nuclearDDRproteins,we
next looked at proteins that shuttle between the cytoplasm and
nucleus and play roles in regulating phosphorylation of DDR pro-
teins.We selected five proteins (PP1, PP2A, PP4, PP6, andWIP1)
andexamined theeffect ofPGAM1knockdownon the localization
of these five proteins using immunofluorescence analysis. Only
WIP1, which was located predominantly in the cytoplasm of con-
trol cells (Figure 4D), shifted to the nucleus in PGAM1-knockdown
cells in response to DNA damage. The other four proteins (PP1,with DAPI (in blue) to visualize nuclei (left panels). Quantitative analysis of phosph
percentage of cells with phospho-g-H2AX foci was determined in all cell populati
Except where noted, all values were derived from three independent experimentPP2A, PP4, and PP6) did not show any changes in their cellular
localization due to loss of PGAM1 in either cell line (Figure 4D).
Moreover, no change in subcellular localization or induction of
PGAM1 protein expression was observed with IR or TMZ treat-
ment (Figure 4E). These results therefore suggest that loss of
PGAM1 expression allows increased export of WIP1 to the nu-
cleus. Consequently, a shift in WIP1 localization from the cyto-
plasm to the nucleus was observed in PGAM1-knockdown cells
using co-immunofluorescence analysis (Figure 4F). To determine
the status of WIP1 protein expression in human glioma samples
and cells lines, we studied the matched samples that have been
used previously for PGAM1 expression analysis. A uniform WIP1
expression was detected in normal brain, normal astrocytes, gli-
oma cell lines, and human glioma tumor samples (Figure S3B).
Moreover, we analyzed WIP1 RNA expression using real-time
PCR analysis and found no significant difference in RNA expres-
sion in gliomas compared with normal brain (Figure S3C). Simi-
larly, U87 and LN319 expressed physiological levels of WIP1
(compared with the WIP1-overexpressing cell lines Lncap and
MCF7), and there was no change in expression of WIP1 upon
PGAM1 knockdown (Figure S3D).
PGAM1 Physically Binds WIP1 in the Cytoplasm
As WIP1 is a phosphatase found in the cytoplasm in the pres-
ence of PGAM1, we hypothesized that PGAM1 binds WIP1 to
block WIP1-mediated interactions with ATM, Chk1, Chk2, and
g-H2AX. We therefore tested whether PGAM1 directly interacts
with WIP1 to restrict movement toward the nucleus by perform-
ing immunoprecipitation and reverse immunoprecipitation using
antibodies specific for PGAM1, WIP1, ATM, Chk1, Chk2, and
g-H2AX. In control cells, PGAM1was detected inWIP1 immuno-
precipitates, and WIP1 was detected in PGAM1 immunoprecip-
itates (Figure 5A; Figure S4A). Moreover, cell fractionation
analysis revealed that PGAM1:WIP1 interaction is present only
in the cytoplasmic fraction (Figure 5B), whereas no other
phosphatases (PP1, PP2A, PP4, or PP6) were found to be immu-
noprecipitated with PGAM1 antibody (Figure S4B). In PGAM1-
knockdown cells, PGAM1 was not detected in WIP1 immuno-
precipitates, and WIP1 was accordingly not detected in
PGAM1 immunoprecipitates (Figure 5C; Figures S4C and
S4D). When the WIP1 antibody was used in PGAM1-knockdown
cells, ATM, Chk1, Chk2, and g-H2AX were all detected in WIP1
immunoprecipitates (Figure 5C; Figure S4D). We also performed
immunoprecipitation using ATM, Chk1, Chk2, or g-H2AX anti-
bodies separately, and WIP1 was detected in each pull-down
in PGAM1-knockdown cells (Figure 5C; Figure S4D). In each
separate immunoprecipitation using a specific antibody target-
ing a DDR protein (ATM, Chk1, Chk2, or g-H2AX), the other
DDR proteins were not detected (Figure 5C; Figure S4D). Impor-
tantly, WIP1 was not observed in control U87 and LN319 cells
immunoprecipitated with ATM, Chk1, Chk2, or g-H2AX anti-
bodies (Figure S4E). Loss of PGAM1 expression therefore allows
WIP1 to associate with key nuclear signaling proteins in the DNA
damage response pathway.o-g-H2AX foci counted on >200 cells per group as indicated (right panels). The
ons treated with either IR (10 Gy) or TMZ (100 mM) at the indicated time points.
s ± SD. *p < 0.05.
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PGAM1 Binds WIP1 Independent of PGAM1 Enzymatic
Activity
To understand if the metabolic enzymatic activity of PGAM1 reg-
ulates the DDR pathway, we reconstituted a kinase-dead form of
PGAM1 in stable PGAM1-knockdown cells (Figure 5D) and
measured PGAM1 activity, DNA damage, and g-H2AX foci for-
mation in U87 and LN319 cells (Figures 5E–5G). As expected,
the PGAM1 enzyme activity, 3PG production, and PPP flux in
cells infected with two mutant (H186R and Y92F) PGAM1 con-
structs were similar to those of PGAM1-knockdown cells. In
contrast, the enzyme activity (Figure 5E), 3PG production, and
PPP flux (Figures S5A and S5B) in cells infected with a wild-
type (WT) shRNA-resistant PGAM1 construct were similar to
those in parental cells. Interestingly, reduction of g-H2AX foci
formation in PGAM1-knockdown cells was rescued by introduc-
tion of either the H186R or Y92F PGAM1 mutant or WT PGAM1
constructs (Figure 5F). As observed earlier, levels of DNA
damage measured by the comet tail assay were elevated and
sustained in PGAM1-knockdown cells, whereas expression of
the mutant forms H186R or Y92F of PGAM1 or WT PGAM1 pre-
vented sustained levels of DNA damage (Figure 5G). Immuno-
precipitation studies revealed that mutant, kinase-dead
PGAM1 is capable of binding to WIP1, similar to endogenous
PGAM1 (Figure 5H). This resulted in cytoplasmic localization of
WIP1, as revealed by immunofluorescence staining (Figure 5I),
suggesting that PGAM1 metabolic activity is not required for
PGAM1-mediated regulation of the DDR pathway.
Silencing of WIP1 Reverses the Effects of PGAM1
Deficiency on IR and TMZ Resistance
Our previous results suggest that PGAM1 loss allows WIP1 to
enter the nucleus and directly interact with and dephosphorylate
Chk1, Chk2, ATM, and g-H2AX, thereby leading to inactivation of
the DDR pathway. We next asked whether silencing of WIP1
expression could reverse the DDR pathway inactivation in
PGAM1-knockdown cells. Furthermore, we also silenced the
expression of the four other previously studied proteins, PP1,
PP2a, PP4, and PP6, and monitored if loss of any of them could
in fact reverse the effect of DDR pathway inactivation due to
PGAM1 deficiency. To test this, we transfected PGAM1-knock-
down cells with pooled siRNAs targetingWIP1, PP1, PP2A, PP4,
and PP6. As shown in Figure 6A, levels of WIP1 protein wereFigure 4. Loss of PGAM1 Inhibits Phosphorylation of ATM and Contro
(A) Isogenically paired U87 and LN319 cells differing only in PGAM1 expression
(100 mM, 3 h), and cells were harvested at 48 h for analysis of pATM (ser1981), ATM
b-actin expression by western blot.
(B) Fluorescence-activated cell sorting (FACS)-based cell cycle phase distribution
Gy) treatment, DMSO, and TMZ treatment (100 mM) treatment. U87-EV and LN319
DMSO treated control.
(C) An ATR (or control IgG) immunoprecipitate (IP) was first prepared and incubate
of ATR-mediated PHAS Ser/Thr phosphorylation was performed.
(D) Western blot analysis of WIP1, PP1, PP2A, PP4, and PP6 from the nuclear (N)
LN319 cells treated once with IR (10 Gy).
(E)Western blot analysis of PGAM1 from the nuclear (N) and cytoplasmic (C) fractio
and TMZ (100 mM).
(F) DAPI (blue)/PGAM1 (green)/WIP1 (red) co-immunofluorescence analysis wa
knockdown U87 cells. Scale bars, 10 mm.
Except where noted, all values were derived from three independent experimentdepleted (almost 80%) in the WIP1 siRNA transfected PGAM1-
knockdown cells. Similarly, levels of PP1, PP2A, PP4, and PP6
were about 90% depleted using the appropriate pooled siRNA
in PGAM1-knockdown cells (Figure S5C). We then treated these
distinct cell populations with IR (10 Gy) or TMZ (100 mM), and
measured g-H2AX foci, apoptosis, and colony formation. Treat-
ment with IR or TMZ led to increased g-H2AX foci formation in
WIP1-deficient, PGAM1-knockdown cells, compared with
WIP1-proficient, PGAM1-knockdown cells (Figures 6B and
6C). In agreement with this, fewer apoptotic cells (Figures 6D
and 6E) and significantly more colonies (Figures 6F and 6G)
were observed in IR (10 Gy) and TMZ (100 mM) treated WIP1-
deficient, PGAM1-knockdown cells compared with WIP1-profi-
cient, PGAM1-knockdown cells. No change in g-H2AX foci
formation and apoptosis was observed in PP1, PP2A, PP4,
and PP6 deficient, PGAM1-knockdown cells compared with
PGAM1-knockdown cells (Figures S5C and S5D).
Loss of PGAM1 Sensitizes Gliomas to IR and TMZ
Treatment In Vivo
To determine if the events noted in vitro are also observed in vivo,
we intracranially injected mice with luciferase-labeled U87 and
LN319 cells infected with viral particles that encode empty
shRNA vector (EV) or PGAM1 shRNA vector. Tumor growth
was monitored by bioluminescence imaging, and tumor-bearing
animals were treated with or without IR or TMZ. Control EV-ex-
pressing tumors grew over a 7 week period (Figure 7A), necessi-
tating the sacrifice of all animals by day 70 post-implantation.
Importantly, tumors expressing PGAM1 shRNA exhibited a
statistically significant reduction in tumor growth relative to EV-
expressing tumors when treated with IR or TMZ (Figure 7A).
This increased sensitivity toward IR and TMZ translated into a
significant survival advantage of 30 days on average for mice
with PGAM1 shRNA#1-expressing tumors (Figure 7B). Further-
more, additional growth inhibition and survival advantage was
noted in animals with PGAM1-knockdown cells treated with
both IR and TMZ (Figure 7B). Moreover, tumors generated
from U87 cells with stable expression of catalytic inactive Y92F
and H186R PGAM1 mutants in an otherwise WT PGAM1-defi-
cient background demonstrated similar resistance to IR and/or
TMZ treatment as the parental PGAM1-proficient tumors (Fig-
ure 7A). Consequently, IR/TMZ treatment did not prolongls Cellular Localization of WIP1
were untreated () or treated (+) with IR (10 Gy) and with vehicle (veh) or TMZ
, pChk1 (ser345), Chk1, pChk2 (thr68), Chk2, pcdc25C (ser216), cdc25C, and
analysis of glioma cells differing only in PGAM1 expression after 7 days of IR (10
-EV, untreated control; U87-PGAM1-shRNA#1 and LN319-PGAM1-shRNA#1,
d with the ATR substrate PHAS, after which awestern blot analysis of the extent
and cytoplasmic (C) fractions of control or PGAM1 shRNA-containing U87 and
ns of parental U87 cells treated oncewith drug vehicle (veh; DMSO), IR (10Gy),
s used to verify the subcellular localization of WIP1 in parental and PGAM1-
s ± SD. * p < 0.05.
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survival in mice carrying tumors expressing catalytic inactive
Y92F and H186R PGAM1 mutants, as seen in animals harboring
PGAM1-deficient tumors (Figure 7B). Upon pathological exami-
nation, PGAM1 knockdown tumors treated with IR and TMZ
were indeed significantly smaller in size compared with corre-
sponding time-matched vehicle-treated tumors (Figure 7C, top
panel). U87 PGAM1 shRNA#1 tumors treated with IR and TMZ
had a decreased proliferative index (MIB1, 22% ± 3.3% and
26% ± 4.5%, respectively; Figure 7C), whereas the untreated
U87 PGAM1 shRNA#1 tumors had a higher proliferative index
(59.4% ± 6.8%). Cleaved caspase-3 levels were elevated in
PGAM1 knockdown tumors treated with IR (33% ± 4.7%) and
TMZ (27% ± 5.1%) compared with vehicle-treated (2% ±
4.3%) tumors. In summary, inhibition of PGAM1 restricted
growth of human GBMs within the intracranial environment in
response to IR and TMZ, with decreased proliferation but
enhanced apoptosis. These results show that loss of PGAM1
sensitizes glioma cells to IR and TMZ treatment in vivo, similar
to the effects of PGAM1 loss in vitro.
DISCUSSION
During cancer initiation and progression, alterations to different
metabolic enzymes promote neoplastic transformation (Hsu
and Sabatini, 2008; Vander Heiden and DeBerardinis, 2017; Kei-
bler et al., 2016). Adding to evidence from previous studies, the
present study shows that same level of PGAM1 overexpression
occurs at every grade (I–IV) of glioma. Moreover, this study dem-
onstrates that PGAM1 overexpression blocks the deactivation of
the DDR pathway, which makes these cells treatment resistant
to different DNA-damaging agents. In normal cells, the DDR
pathway becomes activated whenever there is DNA damage re-
sulting in sequential events of (1) recognition of the damage site,
(2) activation of the DDR pathway, (3) cell-cycle arrest, and finally
(4) deactivation of the DDR pathway (Kim and Haber, 2009).
In these sequential events, PGAM1 overexpression in glioma
appears to play role in blocking the deactivation of the DDR
pathway, thereby making it constitutively active and providing
resistance against IR- and TMZ-mediated DNA damage. In this
study, IR and TMZ treatment produced similar levels of DNAFigure 5. WT and Kinase-Dead PGAM1 Physically Interact with WIP1 a
(A) Western blot analysis of levels of PGAM1, WIP1, Chk1, Chk2, and g-H2AX w
cells with and without IR treatment.
(B) Western blot analysis of WIP1 and PGAM1was performed in PGAM1,WIP1, an
parental U87 cells with and without IR (10 Gy) treatment.
(C) Western blot analysis of levels of PGAM1, WIP1, Chk1, Chk2, and g-H2AX
knockdown U87 cells with and without IR treatment.
(D) Western blot analysis of levels of PGAM1 and FLAG expression in PGAM1 sh
mutant forms (H186R and Y92F) of PGAM1. Western blot analysis of b-actin (bo
(E) PGAM1 activity (mean + SE) of cells from (D) was determined in triplicate for
(F) Quantitative analysis of g-H2AX foci counted on >200 cells per group from (D
H2AX antibody (in red) and counterstained with DAPI (in blue) to visualize nuclei.
(G) Analysis of tail moment (a measure of DNA fragmentation) in cells from (D)
represents the mean + SE of at least 100 cells per treatment.
(H) Western blot analysis of levels of PGAM1 and WIP1 was performed in PGAM
expressing two FLAG tagged kinase-dead mutant forms (H186R and Y92F) of P
(I) DAPI (blue)/PGAM1 (green)/WIP1 (red) co-immunofluorescence analysis was us
dead mutant forms (H186R and Y92F) of PGAM1. Scale bars, 10 mm.
Except where noted, all values were derived from three independent experimentdamage in both parental cells and PGAM1-knockdown cells,
but PGAM1-knockdown cells exhibited inefficient repair as
observed by fewer g-H2AX foci, which indicated a decrease in
initiation of the DDR pathway. Control of DNA repair pathway
activation and deactivation is regulated in a variety of ways,
including through regulators of the metabolic processes.
Previous work demonstrated the role of PGAM1 in DNA dou-
ble-strand break repair by HR through regulation of CtIP (Qu
et al., 2017). This study showed that genetic silencing or pharma-
cological inhibition of PGAM1 in HeLa cells results in CtIP protein
degradation and p53/p73 pathway activation (Qu et al., 2017). In
normal cells, DNA damage results in the formation of DDR foci,
which leads to cell-cycle arrest due to the presence of intact
cell cycle checkpoints, followed by efficient repair, and finally
disassembly of the DDR foci removes the break from cell cycle
progression. In contrast, deregulation of cell proliferation is an
early step in tumorigenesis that elicits DNA replication stress
and ongoing DNA damage formation, which results in activation
of the DDR pathway, specifically activation of the downstream
ATM and ATR pathways characterized by phosphorylation of
ATM, Chk1, Chk2, and g-H2AX. (Bartkova et al., 2005, 2010;
Gorgoulis et al., 2005). But despite DDR activation, as these
tumorigenic cells do not have effective cell cycle checkpoints,
cell-cycle arrest does not occur, and these cells with defective
DNA replicate, thus increasing genomic instability. On the other
hand, constitutively active and efficient DDR provides a common
mechanism for cancer therapy resistance. As such, it has been
reported that glioma stem cells display an efficient DDR pathway
and are refractory to radiation treatment (Bao et al., 2006).
In normal cells, deactivation of DDR foci can occur in a variety
of ways after repair is completed. Reversing PARylation, a post-
translational change, can lead to dissociation of DDR foci (Gagné
et al., 2006). Yeast Pph3, PP1 (Keogh et al., 2006; Bazzi et al.,
2010), and mammalian PP1, PP2A, PP4, PP6, and WIP1 (Naza-
rov et al., 2003; Chowdhury et al., 2005; Nakada et al., 2008; Cha
et al., 2010; Douglas et al., 2010; Macurek et al., 2010; Moon
et al., 2010Chowdhury et al., 2008), and Tip60 phosphatases in
human and Drosophila cells can reverse the phosphorylation of
g-H2AX (Kusch et al., 2004; Jha et al., 2008). Our present study
reveals that PGAM1 overexpression appears to contribute to thend Thereby Block Binding with ATM, Chk1, Chk2, and g-H2AX
as performed in PGAM1, WIP1, and IgG immunoprecipitates from control U87
d IgG immunoprecipitates from the nuclear (N) and cytoplasmic (C) fractions of
was performed in PGAM1, WIP1, and IgG immunoprecipitates from PGAM1-
RNA-expressing U87 cells expressing FLAG-tagged WT and two kinase-dead
ttom of panel) was used to verify equal input.
each group using an assay coupled to the oxidation of NADH.
), following immunofluorescent staining with anti-Ser-139-phosphorylated g-
treated with IR (10 Gy) and harvested after 0, 1, 3, 5, and 7 days. Each point
1, FLAG, and IgG immunoprecipitates in PGAM1 shRNA-expressing U87 cells
GAM1 with and without IR treatment.
ed in PGAM1-knockdownU87 that was rescuedwith two FLAG tagged kinase-
s ± SD. *p < 0.05.
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constitutive activation of the DDR pathway by inhibiting a natural
phosphatase, WIP1, which in normal cells deactivates important
DDR pathway proteins by dephosphorylating them. Per previous
studies, p53 is one of the transcriptional activators of WIP1 and
DNA damage may lead to the activation of p53, followed by
elevated WIP1 activation that downregulates downstream DNA
damage sensing pathway (Fiscella et al., 1997). In our system,
we did not observe any change in expression of WIP1 after
DNA-damaging treatment (IR and TMZ) in p53 WT U87 cells or
in LN319 cells that have been reported to have a mutation in
p53 (Van Meir et al., 1994). These observations indicate that
the link among DNA damage, p53 activation, and WIP1 regula-
tion is not prominent in the context of glioma.Moreover, previous
literature suggests PGAM1 as a negative transcription target of
p53 (Kondoh et al., 2005), and we found overexpression of
PGAM1 in both p53 WT U87 cells as well as p53-mutated
LN319 cells. A contradictory study demonstrated that in rat
cardiomyocyte, p53 upregulates expression of PGAM1 (Ruiz-
Lozano et al., 1999). Our present study demonstrates a p53-in-
dependent role of WIP1 and PGAM1 expression in glioma cells.
Our results advance the current understanding of how
PGAM1 regulates the subcellular localization of WIP1 and
thereby regulates its DDR-related activity. PGAM1 is mostly a
cytoplasmic protein that directly interacts with WIP1 and keeps
it in the cytoplasm. As a result, WIP1 is unable to travel to the
nucleus and is not able to deactivate ATM, Chk1, Chk2, and g-
H2AX by dephosphorylation (Figure 7C). Although the afore-
mentioned findings provide a potentially crucial link between
PGAM1 and treatment resistance through the DDR system
via WIP1 regulation, the linkage is clearly context dependent.
In PGAM1-overexpressing glioma cells, WIP1 is expressed at
the normal physiological level. In this scenario, normal physio-
logical levels of WIP1 most likely control only the DDR pathway
proteins and not the proteins involved in other pathways (e.g.,
p53, p38, NF-kb, ER-a, c-Jun, E2F1) (Lowe et al., 2012).
Conversely there are tumors that express high levels of WIP1,
which then regulate other pathways along with DDR pathway.
Knocking down WIP1 overexpression has been reported to
alter ATM signaling and activate the DDR pathway (Lowe
et al., 2012). Most likely, not all overexpressed WIP1 can bind
with PGAM1 (even if PGAM1 is also overexpressed), resulting
in free WIP1 to perform other functions in addition to DDR regu-
lation. In gliomas, as WIP1 is not overexpressed, and geneti-
cally modifying its expression only results in changes to the
DDR pathway, this strongly suggests that the functional activity
of normal physiological expression of WIP1 is to regulate theFigure 6. Silencing of WIP1 in PGAM-Knockdown Cells Rescues IR an
(A) Levels of WIP1 and b-actin in cells from Figure 2A transfected with a non-targe
with IR (10 Gy) or TMZ (100 mM).
(B) Quantitative analysis of phospho-g-H2AX foci counted on >200 cells per grou
populations treated with IR (10 Gy) at the indicated time points.
(C) Quantitative analysis of phospho-g-H2AX foci counted on >200 cells per g
determined in all cell populations treated with TMZ (100 mM) at the indicated tim
(D and E) Apoptosis in glioma cells from (A) with andwithout IR (10Gy) (D) and (E) w
and flow cytometry analysis after 3, 5, or 7 days of treatment.
(F and G) Number of colonies (>50 cells) that arose in soft agar 28 days following p
and without TMZ (100 mM) treatment.
Except where noted, all values were derived from three independent experimentDDR pathway (Lowe et al., 2012). When it is overexpressed,
it regulates several other pathways (such as stress-induced,
NER, and inflammatory pathways) (Lowe et al., 2012), and in
that setting genetic or pharmacological inhibition of WIP1
may have different functional outcome.
As shown before, the enzymatic role of PGAM1 can be meta-
bolic or non-metabolic in nature (Hitosugi et al., 2012; Qu et al.,
2017). But as a protein, PGAM1 was shown to interact with
ACTA2 (Zhang et al., 2017) and control migration of cancer cells.
Similarly, our work demonstrates WIP1 as a direct interacting
partner of PGAM1. Also, we showed that this interaction is
independent of the enzymatic activity of PGAM1. Tumors that
overexpress PGAM1 not only have accordingly high activity of
this metabolic enzyme but would also possess increased
suppression of WIP1 function through the non-enzymatic, non-
metabolic role of PGAM1 in interacting withWIP1. This activation
of the DDRpathway is shown herein to be very efficient inmaking
glioma cells resistant to standard therapy such as IR and TMZ
chemotherapy.
The non-metabolic control of the DDR pathway supports the
idea that the enzymes involved in the cellular bioenergetics
pathway actually regulate a wider spectrum of events than
was not previously appreciated. This non-metabolic role of
PGAM1 acts as a switch for constitutive activation of the
DDR pathway that promotes therapeutic resistance and can
be exploited by using appropriate inhibitors that can block its
interaction with WIP1, combined with DNA-damaging agents.
We have demonstrated that downregulation of PGAM1 expres-
sion sensitizes glioma cells toward TMZ and IR, thereby
increasing the efficiency of the standard therapeutic regimen
for the treatment of glioma. The present findings have implica-
tions not only for our understanding of how PGAM1 overex-
pression contributes to glioma growth but also for therapy for
PGAM1-overexpressing tumors.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Figure 7. Knocking Down PGAM1 Increases TMZ/IR Sensitivity in Glioma Xenografts
(A) In vivo growth curves of orthotopic, bioluminescence-labeled control, stable PGAM1-silenced, and PGAM1-silenced U87 tumor cells stably expressing one of
two FLAG-tagged kinase-dead mutant forms (H186R and Y92F) of PGAM1. Three weeks post-implantation, the animals were treated with vehicle (DMSO), IR (10
Gy), TMZ (100 mM), or both IR (10 Gy) and TMZ (100 mM). Data are mean ± SD. *p < 0.05, n = 7.
(legend continued on next page)
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
The human glioma cell lines U87, U251, LN319, SF10601, SF7996 and SF8279 were provided by the UCSF Brain Tumor Center
Tissue Core. All cells were cultured as described (Mukherjee et al., 2016; Mukherjee et al., 2013; Fouse et al., 2014; Mancini
et al., 2018), identities were confirmed by short tandem repeat analysis (Promega Geneprint Kit), confirmed mycoplasma negative
(MycoSensor Mycoplasma Detection PCR Assay Kit; Agilent Technologies), and used within 3 passages of thawing.
Animal model
4 weeks old female Immunodeficient mice (nu/ nu; Charles River) were caged (5 animals/cage) and maintained with standard rodent
chow diet andwater ad libitum, under a 12 h light/dark cycle at constant temperature and humidity. The animals weremonitored dailye2 Cell Reports 31, 107518, April 14, 2020
and were sacrificed once neurological symptoms developed and reached the end point as described in the animal protocol.
The guidelines of the UCSF Institutional Animal Care and Use Committee were followed for all animal work.
Human samples
Non-tumor brain tissue samples were obtained from autopsy (N = 2) or from cancer-free epilepsy patients who underwent temporal
lobe resection (N = 3). Formalin-fixed paraffin embedded sections were used for neuropathological verification of tumor grade based
on the WHO classification scheme (Barritault et al., 2018) and identified grade I (juvenile pilocytic astrocytoma, N = 2, adult pilocytic
astrocytoma, N = 3), grade II (diffuse astrocytoma, N = 5), grade III (anaplastic astrocytoma, N = 5), and grade IV (glioblastoma, N = 5)
specimens. All 25 samples (15 male and 10 female, between the age range of 9 70 years.) were obtained from the UCSF Brain
Tumor Research Center Tissue Core (University of California, San Francisco) using protocols approved by the UCSF Institutional Re-




Total-RNA was extracted (RNeasy Kit, QIAGEN), dissolved in nuclease-free water, and analyzed (Agilent 2100 Bioanalyzer). Real-
time PCR was performed in triplicate to measure PGAM1, WIP1, and b-actin mRNA levels. For PGAM1, the 1st set of primers
were forward 5- GGAGGGGAAACGTGTACTGA-3, reverse 5- CAGAGAGACCCTCCAGATGC-3 and 2nd set of primers were forward
50- AACCATGCTAAGCCATGACC-30 and reverse 50- GCAGTGACCTGACTGCAGAA-3.’’ For WIP1, the primers were 5-CTGT
ACTCGCTGGGAGTGAG-3 and 5-GTTCGGGCTCCACAACGATT-3. For b-actin the primers were 5-GATGAGATTGGCAT
GGCTTT-3 and 5- CACCTTCACCGTTCCAGTTT-3. Thermal cycling conditions consisted of an initial step of 95C for 3 minutes fol-
lowed by 40 cycles at 95C for 15 s, 60C for 15 s, and 72C for 30 s (Rotor Gene, QIAGEN).
Modulation of PGAM1 and WIP1 expression
Empty shRNA vectors (EV) or one of two different lentiviral PGAM1 shRNAs, were used to transduce U87 and LN319 cells as
described (Mukherjee et al., 2016; Mukherjee et al., 2013). Parental and PGAM1 knock-down cells were subsequently either tran-
siently transfected (Fugene 6) with pooled siRNA targeting WIP1 (Dharmacon), PP1, PP2A, PP4 and PP6 (Santa Cruz biotechnology)
or transduced with lentiviral constructs encoding three different forms of human FLAG-tagged PGAM1 (WT-shRNA resistant, kinase-
dead PGAM1 H186R, and kinase-dead PGAM1 Y92F). In each case the appropriate scrambled shRNA and siRNA were also used.
Coding sequences of FLAG-PGAM1 and indicated mutants were cloned to pCDNA3.1 vector. Nonsense point mutations to the
underlined nucleotides 50-CCACCCATTTTACAGCAACAT-30 in the corresponding coding sequence of PGAM1 in the pCDNA3.1
plasmid confer resistance to shRNA#1 silencing. WT or mutant PGAM1 reconstituted cells were stable lines generated by Lipofect-
amine 2000 (Invitrogen) transfection followed by G418 selection. Themonoclones used in this study had a comparable expression as
like endogenous PGAM1.
Cell growth assays
Three thousand cells per well were plated onto 96-well plates and cultured overnight in 100 mL of media. Media contained vehicle,
PGAM-tide (MRQIKIWFPNRRMKWKKHHHHHHPWLIRHGE), control peptide (MRQIKIWFPNRRMKWKKHHHHHHPWRIEGHL) (50)
(synthesized from New England Peptide Gardner, MA), and alizarin (60 mM) for 5 days. Cells were then treated with 20 mL Alamar
Blue reagent (Invitrogen) per well for one hour and fluorescence (A540/620) was measured using a Synergy 2 Multi-mode Microplate
reader (BioTek Instruments). Percent cell growth was determined by normalizing fluorescence measurements to media-only controls.
PGAM1 activity assay
U87 and LN319 cells were grown to 25% confluency and were harvested. Soluble proteomes were prepared in 30 mM Tris-HCl (pH
7.0) and tested for PGAM1 activity by monitoring the conversion of 3-phosphoglyceric acid to 2-phosphoglyceric acid at 20C–25C
using an assay coupled to the oxidation of NADH as described by Evans et al., 2015.
Oxidative PPP flux assay
Oxidative PPP flux wasmeasured as described previously (Hitosugi et al., 2012). Briefly, cells were seeded on 60mm dishes within a
100 mm dish that is completely sealed to collect the 14CO2 release from a pinhole. The cells were incubated in 2 mL of medium con-
taining [1-14C]- or [6-14C]-glucose, respectively, at a final specific activity of 10 mCi/ml glucose at 37C for 3 h. By injecting 0.3 mL of
50%TCA from another pinhole oxidative PPP flux was stopped and 0.3 mL of Hyamine Hydroxide was injected to trap 14CO2 release
by placing a small cup. Hyamine Hydroxide was dissolved into 60% methanol and subjected to scintillation counting.
3-PG assay
Cells were homogenized in 1.5mL lysis buffer to determine the concentration of 3-PG as described previously (Hitosugi et al., 2012).
The supernatant from the homogenate were collected by centrifugation at 4C for 10 minutes at 16,000 rpm and were applied toCell Reports 31, 107518, April 14, 2020 e3
Amicon Ultra tubes filter (10KDa cut off, Millipore). NADH, ADP, MgCl2, recombinant LDH and PKM1 proteins were added to the flow
that contain the metabolites at a final concentration of 0.14 mM, 1 mM, 50 mM, 5 mg/ml and 10 mg/ml respectively. Recombinant
enolase protein was added to a final concentration of 50 mg/ml to measure cellular 2-PG. Once the reaction was initiated by enolase,
a decrease in absorbance at 340nm from NADH oxidation was measured by a Synergy 2 Multi-mode Microplate reader (BioTek In-
struments). Recombinant PGAM1 was added (final conc. 25ug/ml) after termination of the enolase reaction and immediately moni-
tored for the absorbance (340nm) to measure cellular 3-PG.
Cell cycle distribution, apoptosis, soft agar assay, and DNA damage foci studies
a. Cell cycle distribution analysis: For cell cycle distribution, fixed, propidium iodide-labeled cells were subjected to flow cytom-
etry using a FACSCalibur (BD Biosciences). Cell cycle and sub-G1 analysis was performed using Flowjo software (Treestar).
b. Apoptosis analysis: For apoptosis analysis, an Annexin-V staining Kit was used (BD PharMingen) and analyzed as per theman-
ufacturer’s instructions.
c. Soft agar assay: Soft agar assays were performed as previously described (‘). Numbers of colonies (> 50 cells) and average
diameter of the colonies for each condition were measured on 100 3 photomicrographs and analyzed using Metamorph Im-
aging Software (Molecular Devices).
d. DNA damage foci analysis: DNA damage foci analysis was carried out by the use of -H2AX-specific primary antibodies (1:200),
and fluorescent-tagged secondary antibodies. Fluorescence microscopy was performed on > 200 cells per group, and the
percentage of cells with -H2AX foci (red foci) was determined as described (Mukherjee et al., 2018).
IHC analysis
Immunohistochemistry was performed on a Ventana Medical Systems Benchmark XT using anti-human PGAM1 (1:250 dilution,
60 min, Abcam), MIB1(1:100, DAKO), cleaved caspase-3 (1:50, Cell Signaling Technology) antibody. Staining was visualized using
3, 30-Diaminobenzidine tetrahydrochloride (Ventana). Negative and positive controls were included in each run. PGAM1 staining was
scored using a four-tier scale: 0, no immunostaining; 1, > 0% to% 10% positive; 2, > 10% to% 25% positive; 3, > 25% to% 75%;
and 4, > 75% tumor cells positive. Ki-67 and cleave caspase-3 staining was scored. The proliferating and apoptotic index (percent-
age) was calculated as the number of positive nuclei over total nuclei.
Comet assay
The DNA damage in the cells was measured using a Comet assay kit (Trevigen, Gaithersburg, MD) according to the manufacturer’s
protocol. As described previously (Ito et al., 2013), after trypsinization and PBSwash, the cells were suspended in a low-temperature-
melting agarose and immediately layered onto Comet Slides (Trevigen). Thirty-minute incubation at 4C allowed the agarose to set.
Then the slides were directly subjected to electrophoresis in neutral buffer before being immersed in DNA precipitation solution for
30 minutes at room temperature. After electrophoresis, the slides were dried, stained using SYBRGreen (Trevigen), and observed by
fluorescent microscope. One hundred cells per treatment were analyzed using the computer-based image analysis system (Comet
Assay, Perceptive Instruments Ltd.). The amount of DNA double strand breaks was quantitated and expressed as the ‘‘tail moment,’’
which combined a measurement of the length of the DNA migration and the relative DNA content.
Cell fractionation, protein extraction, immunoprecipitation, and western blot analysis
Protein lysates from control or PGAM1 knockdown cells and subfractions (NE-PER Extraction kit, Pierce) were prepared in lysis
buffer supplemented with protease and phosphatase inhibitors (Roche). For immunoprecipitation, protein lysates were pre-
cleared with protein A/G-agarose beads (Santa Cruz, 3 hours, 4C), and then incubated with primary antibody (16 hours,
4C). Immune complexes were precipitated (2 hours, 4C) with protein A/G-agarose beads. In control samples, the primary anti-
body was substituted with control IgG. Immunoprecipitates were washed four times with RIPA buffer containing 0.5 M NaCl and
2% SDS, washed three times with PBS, and then resuspended in Laemmli buffer. Proteins were separated on 4%–20%
gradient polyacrylamide gels and transferred onto Immuno-Blot PVDF membranes (Bio-Rad Laboratories). Membranes were
then incubated in blocking buffer (1X TBS containing 5% milk and 0.05% Tween-20, 2 hours), and probed overnight with an-
tibodies specific for the cytoplasmic marker b-tubulin (1:1000), the nuclear marker histone H3 (1:1000), PGAM1 (1:1000), b-actin
(1:20,000), WIP1 (1:1000), caspase-3,(1:1000), PARP (1:1000), pATM (1:2000), ATM, pChk1 (1:2000), Chk1 (all Cell Signaling),
pChk2, Chk2 (1:1000), pcdc25C(1:500)(Santa Cruz), phospho Ser/Thr, ATR, (1:500)(Abcam), PP1, PP2A, PP6, (Santa Cruz)
PP4 (Abcam), CtIP(Abcam) and ACTA2 (Santa Cruz) and washed, then incubated with appropriate horseradish peroxidase-con-
jugated secondary antibodies (Santa Cruz Biotechnology). Antibody binding was detected by incubation with ECL reagents
(Amersham Pharmacia Biotech).
ATR activity assay
Cell lysates from parental and PGAM1 knockdown cells were generated 6 hours after TMZ treatment as described previously (Ito
et al., 2013). Briefly, the lysatewas sonicated, incubated overnight at 4Cwith an antibody targeting ATR or IgG, and then precipitated
with agarose A/G beads (1 hour, 4C). The beads were washed and then incubated, and the reaction products were separated on ae4 Cell Reports 31, 107518, April 14, 2020
15% SDS-polyacrylamide gel and subjected to immunoblotting with anti-phospho-serine threonine substrate antibody (Cell
Signaling) or anti-ATR (Santa Cruz) goat polyclonal antibodies to assure equivalent kinase abundance.
Immunofluorescence staining
Cultured cells grown overnight in 4-well chambered slides were fixed in paraformaldehyde (4%, 10minutes). For antigen unmasking,
slides were placed in 1 mM EDTA pH 8 (10 minutes, 100C under pressure) followed by 15 min at a sub-boiling temperature. After
rinsing twice in PBST, all slides were blocked (3% normal goat serum and 0.2% Triton X-100 in PBS, 30 min, room temperature), and
then incubated with PGAM1 (1:200) and WIP1 (1:100) primary antibodies in 1% goat serum and 0.2% Triton X-100 in PBS (18–20
hours, 4C). After washing, slides were incubatedwith fluorescent-tagged secondary antibodies (647, 588, 1:200, 2 hours, Invitrogen)
appropriate for the host species of the primary antibody. Following washing (PBS, 3x5min each), sections were incubated with DAPI,
washed, and mounted. Negative controls for antibody labeling were performed by omitting primary or secondary antibodies.
In vivo studies
Immunodeficient mice (nu/ nu; Charles River) (n = 7 in each group) were injected intracranially with 4 3 105 luciferase-expressing
U87-empty vector (EV), U87-PGAM1 shRNA#1, U87-PGAM1 shRNA -H186R-FLAG, U87-PGAM1 shRNA and U87-PGAM1 shRNA
-Y92F-FLAG cells. Tumor growth was monitored weekly by treating mice with D-luciferin (150 mg/kg IP, Gold- Biotechnology) and
measuring bioluminescence using a Xenogen IVIS Bioluminescence imaging station (Caliper). Tumor growth was calculated by
normalizing luminescence measurements to Day 1 post-injection values. Three weeks after implantation, the animals were treated
with vehicle (veh, DMSO); IR (3Gy each on 21st,28th and 35th day post tumor cell implantation) or TMZ (5mg/kg dissolved in ora plus
q.d. from 21st-25th and 35th-40th day post tumor cell implantation). The animals were monitored daily for any neurological signs and
were sacrificed once symptoms developed and reached the end point as described in the animal protocol. Kaplan–Meir survival
curves were generated by plotting days of survival following implantation. The guidelines of the UCSF Institutional Animal Care
and Use Committee were followed for all animal work.
Measurement of homologous recombination (HR) and non-homologous end joining (NHEJ) efficiency:
HR and NHEJ efficiency of the parental and PGAM1 knockdown cells was evaluated using the Traffic Light Reporter (TLR) system
(Certo et al., 2011). pCVL Traffic Light Reporter 1.1 (SceI target) EF1 Puro and pCVL-SFFVd14GFP EF1sHA.NLS.Sce (opt) were a gift
from A.Scharenberg (Addgene plasmid #31482 and #31476). We performed assays using U87 and LN319 parental and PGAM1
knockdown cells that were stably integrated with TLR construct, which if repaired accurately by HR using the provided HR donor
sequence after ISceI mediated cut will results in green signals from intact GFP sequence or if undergoes NHEJ then will generate
red signal from mCherry sequence. The cells were co-transfected with DNA plasmids containing an HR donor and ISceI enzyme.
At 3 days post treatment, cells were analyzed by flow cytometry. Data shown are normalized with non-transduced control cells
(not infected with ISceI carrying virus). ATM inhibitor Ku55933 and DNA ligase-4 inhibitor SCR7 (SelleckChemicals) was used as a
positive control for HR and NHEJ inhibition respectively (53).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are reported asmean ± standard error of at least three experiments. When two groups were compared, the unpaired Student’s t
test was applied.Whenmultiple groups were evaluated, the one-way ANOVA test with post hoc Tukey–Kramer multiple comparisons
test was used. p < 0.05 was considered statistically significant.Cell Reports 31, 107518, April 14, 2020 e5
